Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for approval of bempedoic acid / ezetimibe (Nustendi) for treatment of primary hypercholesterolaemia and mixed dyslipidaemia

Bempedoic acid and ezetimibe are low-density lipoprotein lowering compounds that have complementary mechanisms of action. Nustendi will be available as 180 mg / 10 mg film-coated tablets.


European Medicines Agency